InVitria
The advent of recombinant antibody production in mammalian cell lines has revolutionized modern medicine. Clinical success of these agents has challenged the underlying biological manufacturing systems to produce quantities sufficient to supply the ever-expanding commercial markets. A fundamental focus for commercialization efforts was the optimization of cell culture media components utilized in the biologic manufacturing process.
Watch Now
Monoclonal antibody-based therapeutics are well established in the pipelines of biopharmaceutical organizations and have decades of development ahead. However, not all of them have disclosed or confirmed amino acid sequences. Ultra-high-performance liquid chromatography mass spectrometry provides a powerful tool to obtain the sequence information to the residue level. Historically, the process has needed expert users and therefore was extremely low throughput and is often outsourced.
Watch Now
Dr. Katalin Karikó will talk about her pioneering research in mRNA vaccine technology. The Hungarian-born biochemist’s discoveries provided scientists with the tools necessary to develop mRNA vaccines for COVID-19. For her entire career, Dr. Kariko has focused on messenger RNA, or mRNA, the genetic script that carries DNA instructions to each cell’s protein-making machinery. She was convinced mRNA could be used to instruct cells to make their own medicines, including vaccines.
Watch Now
Today millions of patients suffer or die from diseases that will be treatable or even preventable tomorrow. For 200 years, biopharma has steadfastly produced medicines to address unmet medical needs. But in the last 20 years or so, the notion of ‘programmable medicines’ has emerged as a possibility to dramatically transform these production rates.
Watch Now